News

Caretaker Medical Receives Inaugural Healthcare Tech Innovation Award and $200,000 Grant from Medical Society of D.C.

Caretaker Medical is honored to announce it has been awarded the Healthcare Technology Innovation Award, along with a $200,000 grant, from the Medical Society of the District of Columbia (MSDC) at the 5th annual Capital Healthcare Honors Gala. This prestigious award, presented on March 26, 2025, recognizes Caretaker Medical’s groundbreaking work in advancing wireless patient monitoring with its VitalStream platform.

The award, supported by a grant from The Institute for Technology in Healthcare, commemorates the legacy of Dr. Cesar A. C. Caceres, an esteemed medical professional dedicated to the application of technology to solve healthcare challenges. Dr. Caceres founded the Institute for Technology in Healthcare and was recognized for his pioneering work in computer-electrocardiographic interpretive systems.

“We are delighted to celebrate the memory and achievements of Dr. Caceres by presenting Caretaker Medical with this inaugural award,” said Matthew Lecuyer, MD, Healthy Physician Foundation board chair. “As technology improves patient care and physician wellbeing, this award connects the achievements of the past with the promise of the future.”

Caretaker Medical’s CEO, Jeff Pompeo, accepted the award on behalf of the company, expressing gratitude for the recognition of their commitment to improving patient care and physician health. “This award validates our dedication to providing patients and physicians with a much-needed wearable, continuous blood pressure monitoring solution,” said Pompeo.

VitalStream, Caretaker Medical’s US Food and Drug Administration-cleared wearable monitor, merges clinical accuracy with a wire-free, comfortable patient experience. The $200,000 grant will support the expansion of this innovative platform, which provides continuous blood pressure and hemodynamic monitoring.

The technology has demonstrated versatility in routine care and crisis response, proving invaluable in applications such as maternal health monitoring, perioperative recovery, and during the recent IV fluid shortages caused by Hurricane Helene. In these challenging times, VitalStream has helped healthcare providers maintain continuous blood pressure monitoring, ensuring patient safety and optimizing fluid management.

“VitalStream offers significant advantages for patients and providers in routine conditions, as well as unexpected and demanding circumstances,” said Johnny Mann, vice president of sales and marketing at Caretaker Medical. “Our technology can help ensure patient safety and optimize fluid management during some of the most challenging times.”

Caretaker Medical extends its deepest gratitude to the MSDC and The Institute for Technology in Healthcare for this honor and for their tireless efforts to advance healthcare in the Nation’s Capital Region and beyond.

Learn more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like